What is Slu-pp-332 capsule?

332 capsule

SLU-PP-332 is a synthetic, orally bioavailable small molecule first identified and characterized by researchers at Saint Louis University. It is not a hormone, such as an anabolic steroid, nor is it a conventional stimulant. Instead, SLU-PP-332 belongs to a pioneering class of compounds known as ERR (Estrogen-Related Receptor alpha) agonists.

To understand its significance, one must first appreciate the role of ERR . This protein is a transcription factor, often termed a "master regulator" of energy metabolism. It resides within the nucleus of cells, primarily in tissues with high energy demands, such as skeletal muscle, the heart, and the nervous system. ERR controls the expression of a vast network of genes responsible for mitochondrial biogenesis (the creation of new mitochondria), fatty acid oxidation (the breakdown of fats for energy), and oxidative phosphorylation (the process of generating cellular energy, ATP). Under normal physiological conditions, ERR 's activity is limited without its binding partners. SLU-PP-332 functions as a potent and selective synthetic ligand that binds to and potently activates ERR , effectively "switching on" this entire energy-producing genetic program.

A capsule formulation of SLU-PP-332 is the most probable delivery method for human administration, designed to ensure stable absorption into the bloodstream and systemic distribution to target tissues.

332 1

Benefits of SLU-PP-332 Capsule

In experiments with aged mice, mice given SLU-PP-332 ran longer on treadmills and had stronger leg muscles.

Studies have shown that it can encourage the body to burn more fat for energy and reduce reliance on carbohydrates.

In obese mice, it has shown the potential to improve glycemic regulation and reduce fatty liver.

The ability to increase functional muscle mass makes SLU-PP-332 a compelling candidate for treating age-related muscle wasting (sarcopenia) and genetic muscular dystrophies, where preserving muscle quality and quantity is a primary therapeutic goal.

This group of rare genetic disorders is characterized by dysfunctional mitochondria, leading to profound muscle weakness and exercise intolerance. A drug that can upregulate mitochondrial biogenesis and function could be a paradigm-shifting therapy.

As mentioned, the cardioprotective and neuroprotective effects observed in animal models warrant investigation in human populations suffering from heart failure, post-heart attack sequelae, Alzheimer's disease, and ALS.

The profound endurance-enhancing effects will undoubtedly make SLU-PP-332 a high-value target for athletic doping.